NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS NASDAQ) stock market data APIs
$20.3651
0.77(3.8%)
as of October 13, 2026
Try our APIs with
free plan!
NewAmsterdam Pharma Company N.V. Ordinary Shares Financial Data Overview
Price chart is built with
Anychart
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Prev. Close
20.3651
Open
21.1368
High
21.5213
Low
20.0599
52 wk Range
20.04-42.205
Market Cap
2 360 M
Shares Outstanding
117 M
Revenue
7 121 K
EPS
-0.52
Beta
0.1
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with NewAmsterdam Pharma Company N.V. Ordinary Shares (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NewAmsterdam Pharma Company N.V. Ordinary Shares data using free add-ons & libraries
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental Data
NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental data includes:
- Net Revenue: 7 121 K
- EBITDA: -244 163 008
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.48
Get NewAmsterdam Pharma Company N.V. Ordinary Shares End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NewAmsterdam Pharma Company N.V. Ordinary Shares News
New
Group 1 Automotive and 4 More Stocks See Action From Activist Investors
Activists also report to the SEC on NewAmsterdam Pharma, Tennant, Colliers International Group, and Kinetik Holdings. Continue Reading
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinic...
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
NewAmsterdam Pharma N.V. - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer's disease who do not have noticeable memory or functional symptoms- -...
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco...
Get NewAmsterdam Pharma Company N.V. Ordinary Shares fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.